Related Experiment Video
Updated: Sep 19, 2025
06:05
Enema of Traditional Chinese Medicine for Patients with Severe Acute Pancreatitis
Published on: January 27, 2023
24.4K
Senolytic effects of a modified Gingerenone A
Ruin Moaddel1, Chad Sanehira2, Gregory Keyes3
1Laboratory of Clinical Investigation, National Institute on Aging, Intramural Research Program, NIH, Baltimore, MD, USA. moaddelru@mail.nih.gov.
Npj Aging
|May 30, 2025
Summary
Gingerenone A (GinA) and its modified versions (modGinA) show senotherapeutic potential by clearing senescent cells. These compounds improved aging phenotypes and enhanced metabolic and mitochondrial functions in mice.
Area of Science:
- Biochemistry
- Gerontology
- Pharmacology
Background:
- Senescent cells accumulate with aging, contributing to age-related diseases and functional decline.
- Senolytics, which eliminate senescent cells, show promise in improving aging phenotypes and chronic disease health.
- Few senotherapeutic compounds (senolytics and senomorphics) have been identified to date.
Purpose of the Study:
- To investigate the senotherapeutic properties of gingerenone A (GinA) in a mouse model of senescence.
- To evaluate modified GinA compounds (modGinA) with eicosapentaenoic acid (EPA) or docosahexaenoic acid (DHA) esters for enhanced senolytic and senomorphic effects.
Main Methods:
- Administered GinA and modGinA to a mouse model of senescence.
- Assessed biochemical and histological changes.
- Evaluated improvements in metabolic and mitochondrial functions.
Main Results:
- Both GinA and modGinA demonstrated senotherapeutic effects, including anti-inflammatory, senolytic, and senomorphic actions.
- Biochemical and histological markers indicated a reduction in senescence.
- Significant improvements in metabolic and mitochondrial functions were observed in treated mice.
Conclusions:
- GinA possesses senotherapeutic properties.
- Modified GinA compounds (modGinA) enhance the effects of GinA.
- These findings suggest potential therapeutic applications for GinA and modGinA in combating aging and related diseases.
Related Concept Videos
01:19Oral Hypoglycemic Agents: α-Glucosidase Inhibitors
278
α-glucosidase inhibitors, including acarbose (Precose), miglitol (Glyset), and voglibose (Voglib) (primarily available in Asia), are drugs that control blood sugar levels by delaying the digestion of starch and disaccharides. They achieve this by inhibiting α-glucosidase enzymes in the intestine, which slow the absorption of carbohydrates in the intestine, which in turn leads to a prolonged release of the glucoregulatory hormone GLP-1 from intestinal L-cells.
Acarbose and miglitol are...
Acarbose and miglitol are...
278
01:16Antianginal Drugs: Nitrates and β-Blockers
771
In cardiovascular health, antianginal drugs combat angina pectoris — a condition marked by chest pain owing to diminished blood flow to the heart.
Organic nitrates, such as nitroglycerin, play a pivotal role. Once metabolized, they liberate nitric oxide, a molecular marvel. Nitric oxide triggers guanylyl cyclase and augments cGMP production. This biochemical cascade orchestrates the relaxation of vascular smooth muscles, ushering in vasodilation and enhancing coronary blood flow....
Organic nitrates, such as nitroglycerin, play a pivotal role. Once metabolized, they liberate nitric oxide, a molecular marvel. Nitric oxide triggers guanylyl cyclase and augments cGMP production. This biochemical cascade orchestrates the relaxation of vascular smooth muscles, ushering in vasodilation and enhancing coronary blood flow....
771
01:23Dipeptidyl Peptidase 4 Inhibitors
271
Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...
271
01:27Combined Effects of Drugs: Synergism
4.9K
Synergism is a useful mechanism where combining two or more drugs is more effective than each constituent used alone. Such combinations are also called supra-additive interactions. The drugs collectively enhance the final therapeutic effect by acting on different targets. Another advantage is that the low dose of each constituent drug is sufficient to achieve the desired effect. This helps reduce the duration of therapy and lower the adverse effects of these drugs.
Such synergistic combinations...
Such synergistic combinations...
4.9K
01:06Oral Hypoglycemic Agents: Glinides
274
Repaglinide (Prandin) and Nateglinide (Starlix), known as glinides, are oral insulin secretagogues that stimulate insulin release from pancreatic β cells by closing the ATP-sensitive potassium channels (KATP channel). Repaglinide controls insulin release from pancreatic β cells by managing potassium efflux. It shares two binding sites with sulfonylureas and also has a unique site, indicating overlapping mechanisms of action. With a rapid onset and a 4-7 hour duration, it effectively...
274